Psychiatrist characteristics that influence use of buprenorphine medication-assisted treatment

Journal of Addiction Medicine

Volumn 4, Issue 4, 2010, Pages 197-203

  Albright, Joann ^a   Ciaverelli, Robert ^a   Essex, Alyson ^a   Tkacz, Joseph ^a   Ruetsch, Charles ^a  

^a Magellan Health Services ^*  (United States)

Author keywords

Addiction; Buprenorphine; Maintenance; Opioid dependence; Therapy

Indexed keywords

EID: 78649801481     PISSN: 19320620     EISSN: 19353227     Source Type: Journal    
DOI: 10.1097/ADM.0b013e3181c816f3     Document Type: Article

References (28)

1. Center for Substance Abuse Treatment. Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs. Treatment improvement protocol (TIP) Series 43. DHHS Publication No. (SMA) 05-4048. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2005.
2. Drug Addicted Treatment Act. 2000. Available at: http://buprenorphine. samhsa.gov/fulllaw.html. Accessed June 8, 2009.
3. Feroni I, Peretti-Watel P, Paraponaris A, et al. French general practitioners' attitudes and prescription patterns toward buprenorphine maintenance treatment: Does doctor shopping reflect buprenorphine misuse? J Addict Dis 2005;24:7-22. (Pubitemid 41542392)
4. Geller G, Levine DM, Mamon JA, et al. Knowledge, attitudes, and reported practices of medical students and house staff regarding the diagnosis and treatment of alcoholism. JAMA 1989;261:3115-3120. (Pubitemid 19133354)
5. Gordon AJ, Liberto J, Granda S, et al. Outcomes of DATA 2000 certification trainings for the provision of buprenorphine treatment in the Veterans Health Administration. Am J Addiction 2008;18:459-462.
6. Jenkinson RA, Clark NC, Fry CL, et al. Buprenorphine diversion and injection in Melbourne, Australia: An emerging issue? Addiction 2005; 100:197-205. (Pubitemid 40255377)
7. Kissin W, McLeod C, Sonnefeld J, et al. Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opiod dependence. J Addict Dis 2006;25:91-103. (Pubitemid 44707293)
8. Knudsen HK, Ducharme LJ, Roman PM. Early adoption of buprenorphine in substance abuse treatment centers: Data from the private and public sectors. J Subst Abuse Treat 2006;30:363-373. (Pubitemid 43729149)
9. Knudsen HK, Ducharme LJ, Roman PM. The adoption of medications in substance abuse treatment: Associations with organizational characteristics and technology clusters. Drug Alcohol Depend 2007;87:164-174. (Pubitemid 46215923)
10. McKeown A, Matheson C, Bond C. A qualitative study of GPs' attitudes to drug misusers and drug misuse services in primary care. Fam Pract 2003;20:120-125. (Pubitemid 36511936)
11. Miller NS, Sheppard LM, Colenda CC, et al. Why physicians are unprepared to treat patients who have alcohol- and drug-related disorders. Acad Med 2001;76:410-418. (Pubitemid 32417323)
12. National Center on Substance Abuse at Columbia University. Missed Opportunity: National Survey of Primary Care Physicians and Patients on Substance Abuse. New York: National Center on Substance Abuse at Columbia University, 2000.
13. Netherland J, Botsko M, Egan J, et al. Factors affecting willingness to provide buprenorphine treatment. J Subst Abuse Treat 2009;36:244-251.
14. Physician Clinical Support System-Buprenorphine (PCSS). 2009. Available at: http://www.pcssmentor.org. Accessed October 6, 2009.
15. Polydorou S, Gunderson EW, Levin FR. Training physicians to treat substance use disorders. Curr Psychiatry Rep 2008;10:399-404.
16. Robinson GM, Dukes PD, Robinson BJ, et al. The misuse of buprenorphine and a buprenorphine-naloxone combination in Wellington, New Zealand. Drug Alcohol Depend 1993;33:81-86. (Pubitemid 23219912)
17. Roche AM, Richard GP. Doctors' willingness to intervene in patients' drug and alcohol problems. Soc Sci Med 1991;33:1053-1061.
18. Rosenheck R, Kosten T. Buprenorphine for opiate addiction: Potential economic impact. Drug Alcohol Depend 2001;63:253-262. (Pubitemid 32545411)
19. SAMHSA. Treatment Episode Data Set (TEDS) Highlights-2007. National Admissions to Substance Abuse Treatment Services. Rockville, MD; SAMHSA, 2007:1-29.
20. Stanton A, McLeod C, Kissin W, et al. Evaluation of the Buprenorphine Waiver Program: Results from SAMHSA/CSAT's Evaluation of the Buprenorphine Waiver Program: The College on Problems on Drug Dependence PowerPoint Presentation. 2005. Available at: http://buprenorphine.samhsa.gov/findings.pdf. Accessed October 5, 2009.
21. Stanton A, McLeod C, Luckey B, et al. SAMHSA/CSAT Evaluation of the Buprenorphine Waiver Program Expanding Treatment of Opioid Dependence: Initial Physician and Patient Experiences With the Adoption of Buprenorphine. PowerPoint Presentation. 2006. Available at: http://buprenorphine.samhsa.gov/ASAM-06- Final-Results.pdf. Accessed October 6, 2009.
22. Stoller KB, Bigelow GE, Walsh SL, et al. Effects of buprenorphine/ naloxone in opioid-dependent humans. Psychopharmacology (Berl) 2001;154:230-242. (Pubitemid 32247184)
23. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. 2009. Available at: http://www.oas.samhsa.gov/NSDUH/2k7NSDUH/ tabs/Sect1peTabs1to46.htm#Tab1.1A. Accessed June 8, 2009.
24. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. 2007 National Survey on Drug Use & Health: National Results. 2007. Available at: http://www.oas.samhsa.gov/nsduh/2k7nsduh/Alts.htm. Accessed June 23, 2009.
25. Thomas CP, Reif S, Haq S, et al. Use of buprenorphine for addiction treatment: Perspectives of addiction specialists and general psychiatrists. Psychiatr Serv 2008;59:909-916.
26. Vidal-Trecan G, Varescon I, Nabet N, et al. Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France. Drug Alcohol Depend 2003;69:175-181. (Pubitemid 36262027)
27. Walley AY, Alperen JK, Cheng DM, et al. Office-based management of opioid dependence with buprenorphine: Clinical practices and barriers. J Gen Intern Med 2008;23:1393-1398.
28. Wolff K, Farrell M, Marsden J, et al. A review of biological indicators of illicit drug use, practical considerations and clinical usefulness. Addiction 1999;9:1279-1298. (Pubitemid 29433788)